MDXG
MIMEDX GROUP, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.97
+0.51%Oct 28, 2026, 20:03 UTC
MiMedx Group obtained a favorable federal court ruling in the AXIOFILL regulatory classification matter during the third quarter of 2026.
Source:Oct 28, 2026, 20:03 UTC
MiMedx Group reported its operating and financial results for the third quarter of 2026, including continued double-digit year-over-year surgical franchise volume growth and sequential and year-over-year wound care center volume growth.
Source:Oct 28, 2026, 20:01 UTC
MiMedx Group announced a patent license agreement with an unnamed wound care competitor resolving allegations of patent infringement, valued at $25 million.
Source:Oct 16, 2026, 16:08 UTC
Sanara MedTech Inc. and MIMEDX GROUP, INC.'s deal spread widened after the Federal Trade Commission issued a second request in connection with their deal.
Source:Oct 14, 2026, 20:01 UTC
MiMedx Group announced that it will report third-quarter 2026 operating and financial results after the market close on October 28, 2026, followed by a management webcast and conference call at 4:30 p.m. Eastern Time.
Source:Sep 23, 2026, 20:01 UTC
A federal court vacated the FDA's determinations that MiMedx's AXIOFILL product is not minimally manipulated and should be classified as a biological product.
Source:Aug 29, 2026, 10:34 UTC
Sanara MedTech Inc. agreed to be acquired by MiMedx Group, Inc. for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share.
Source:Jul 29, 2026, 20:07 UTC
MiMedx Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook on a standalone basis.
Jul 29, 2026, 20:01 UTC
MiMedx Group announced it will acquire Sanara MedTech in a cash and stock transaction valued at $35 per share with a total enterprise value of approximately $350 million.